◀ Back to PPARA
CYP4A22 — PPARA
Pathways - manually collected, often from reviews:
Text-mined interactions from Literome
Ip et al., Hepatology 2003
(Choline Deficiency...) :
In conclusion,
PPARalpha activation both
increases Cyp4a expression and enhances hepatic lipid turnover ; the latter effect removes fatty acids as substrate for lipid peroxidation and is sufficiently powerful to prevent the development of dietary steatohepatitis
Bretillon et al., Lipids 2003
(Body Weight) :
In the present work, CFAM ( 0.5 % of the diet ) were administered for 3 wk to wild-type and PPARalpha-null mice of both genders to elucidate the
role of
PPARalpha in mediating the effects of CFAM on the activity of acyl-CoA oxidase ( ACO ) and omega-laurate hydroxylase (
CYP4A ), the regulation of which is known to be dependent on the PPARalpha
Ito et al., Mol Cell Biochem 2006
:
The localization of CYP4A and
PPAR isoforms and the
effect of PPAR agonists on
CYP4A protein level and activity were determined in rat kidney and liver
Hardwick et al., PPAR research 2009
:
In hepatic steatosis and steatohepatitis, the omega-oxidation cytochrome P450
CYP4A gene expression is
increased even with reduced hepatic levels of
PPARalpha
Belury et al., Toxicol Appl Pharmacol 1998
:
The
involvement of
PPAR in the peroxisome proliferator mediated induction of fatty acid metabolizing genes such as acyl-CoA oxidase ( ACO ), fatty acid binding protein (FABP), and
cytochrome P450IVA1 ( CYP4A1 ) has been clearly demonstrated